322 results on '"Montefusco, V."'
Search Results
2. Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients
3. Reward anticipation and trait anhedonia: An electrophysiological investigation in subjects with schizophrenia
4. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
5. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
6. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
7. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
8. PERSISTENCE OF EXTRAMEDULLARY DISEASE BY PET/CT IS AN INDEPENDENT PREDICTOR OF ADVERSE OUTCOME AFTER ALLOGENEIC TRANSPLANT IN MULTIPLE MYELOMA: PH-P515
9. IMPACT OF SMOKING ON OVERALL SURVIVAL, NON RELAPSE MORTALITY AND SECOND CANCERS AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES: PH-P363
10. Successful second autologous engraftment after long duration storage of hematopoietic stem cells
11. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
12. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
13. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
14. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma
15. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy
16. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy
17. Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures
18. Allo-HSCT enhances the therapeutic effect of lenalidomide: P891
19. Value of chest X-ray in the diagnosis of lung infections during neutropenic phase of reduced-intensity allogeneic transplantation: P784
20. Immune reconstitution inflammatory syndrome associated with Aspergillus terreus pulmonary infection in an autologous stem cell transplant recipient
21. Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample o outpatients with schizophrenia and their unaffected relatives
22. Bortezomib induction prior to reduced-intensity autologous transplantation followed by lenalidomide consolidation/maintenance in elderly untreated myeloma patients: O159
23. Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM: A451
24. Bortezomib or Lenalidomide to Treat Disease Relapse After Allogeneic Transplantation in Myeloma: A426
25. Cytarabine-Based Regimens for Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma: A284
26. Long-Term Outcome After Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A274
27. PAD-MEL100-LP-L in Elderly Untreated Myeloma Patients: A097
28. Reduced-intensity allogeneic stem cell transplantation using related haploidentical donors for relapsed or refractory lymphomas: evidence of anti-tumour activity in poor prognosis disease
29. Disorganization and cognitive impairment in schizophrenia: new insights from electrophysiological findings
30. Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation
31. Unrelated bone marrow transplantation with reduced - intensity regimen in high-risk patients for age or disease: a prospective GITMO study
32. Tandem auto-miniALLO approach for newly diagnosed multiple myeloma: an update of the Italian experience
33. Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2)
34. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives
35. PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS
36. Social cognition in people with schizophrenia: a cluster-analytic approach
37. PREVALENCE OF OCULAR DISORDERS IN MULTIPLE MYELOMA
38. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
39. Concamitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient
40. ELECTROPHYSIOLOGICAL INDICES OF REWARD ANTICIPATION ABNORMALITIES IN SUBJECTS WITH SCHIZOPHRENIA
41. PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (VPD) AS INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYELOMA CANDIDATES TO AUTOLOGOUS TRANSPLANT
42. ALLOGENEIC TRANSPLANTATION IN HODGKIN'S LYMPHOMA AFTER A FAILED AUTOGRAFT: LONG TERM OUTCOMES AND GRAFT-VERSUS-HOST DISEASE FREE/RELAPSE-FREE SURVIVAL (GRFS)
43. Validation of the Italian Version of the “abnormal Bodily Phenomena Questionnaire” in a Sample of Patients with Schizophrenia: Preliminary Data
44. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
45. Neurophysiological correlates of negative symptom domains: an auditory oddball study in schizophrenia
46. Relazione fra la forma urbana e i luoghi dell’alimentazione: dal rilievo manuale all'optioneering. Seconda parte: I luoghi dell’alimentazione e i percorsi a vocazione artistico monumentale: optioneering e valutazione parametrica
47. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma
48. Allografting from unrelated donors in multiple myeloma: a study by the Italian bone marrow donor registry
49. Electrophysiological investigation of impulsiveness in patients with bulimia nervosa: evidence of reduced inhibitory control
50. Perception of body shape distortion in bulimia nervosa: an ERP study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.